It’s the same question sickle cell patients nationwide have been asking since the ... where technicians will use a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell disease in an early-stage trial ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

its CRISPR medicine for sickle cell and beta thalassemia. We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where CRISPR ...